A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
Public ClinicalTrials.gov record NCT06580938. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF PF-07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS
Study identification
- NCT ID
- NCT06580938
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 4 participants
Conditions and interventions
Conditions
Interventions
- PF-07921585 Biological
- Sasanlimab Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 10, 2024
- Primary completion
- Jul 13, 2025
- Completion
- Jul 13, 2025
- Last update posted
- Mar 22, 2026
2024 – 2025
United States locations
- U.S. sites
- 9
- U.S. states
- 5
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group | Fayetteville | Arkansas | 72703 | — |
| Highlands Oncology Group | Rogers | Arkansas | 72758 | — |
| Highlands Oncology Group | Springdale | Arkansas | 72762 | — |
| Presbyterian/St. Lukes Medical Center | Denver | Colorado | 80218 | — |
| Sarah Cannon Research Institute at HealthONE | Denver | Colorado | 80218 | — |
| Florida Cancer Specialists Sarasota Drug Development Unit | Sarasota | Florida | 34232 | — |
| START Midwest | Grand Rapids | Michigan | 49546 | — |
| Sarah Cannon Research Institute- Pharmacy | Nashville | Tennessee | 37203 | — |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06580938, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 22, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06580938 live on ClinicalTrials.gov.